Melanotan II vs Modafinil
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both Melanotan II and Modafinil can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Melanotan II Modafinil
Weight — 273.35 Da
Half-life ~2 hours ~12-15 hours
Type Synthetic alpha-MSH analog Diphenylmethylsulfinylacetamide (C15H15NO2S)
Key Benefits
Melanotan II
01 Rapid tanning without UV exposure
02 Enhanced sexual function and libido
03 Appetite suppression
04 Improved mood via melanocortin activation
05 Photoprotection through increased melanin
Modafinil
01 Sustained wakefulness and alertness for 10-15 hours without the jitteriness of traditional stimulants
02 Enhanced executive function, working memory, and decision-making under fatigue
03 Improved focus and concentration during prolonged cognitive tasks
04 Reduced impulsivity and improved task completion in sleep-deprived individuals
05 Low abuse potential relative to amphetamine-class stimulants (Schedule IV)
06 Minimal impact on normal sleep architecture when taken in the morning
Dosing Protocols
Melanotan II
Loading: Start 0.25mg daily, increase to 0.5-1mg; Maintenance: 0.5-1mg 2-3x weekly / Loading phase: Daily for first week, then tanning maintenance 2-3x weekly or as needed for sexual enhancement
Initial loading phase 0.25mg 1x daily
Tanning maintenance 0.5-1mg 2-3x weekly
Sexual enhancement 0.5-1mg As needed
Minimal side effects 0.1-0.25mg Every other day
Photoprotection 0.5mg 2x weekly
Modafinil
100-200 mg/day / Once daily (morning)
Side Effects
Melanotan II
Nausea (pre-treatment with antiemetics recommended)
Facial flushing
Temporary blood pressure elevation
Fatigue
Spontaneous erections
Modafinil
Headache (most frequently reported side effect, often dose-dependent)
Insomnia (particularly if taken too late in the day)
Anxiety and nervousness
Appetite suppression and mild nausea
Dry mouth
Dizziness
Gastrointestinal discomfort (diarrhea, abdominal pain)
Contraindications
History of melanoma or dysplastic nevi
Pregnancy or breastfeeding
Cardiovascular conditions
Uncontrolled hypertension
Known hypersensitivity to modafinil or armodafinil
History of Stevens-Johnson Syndrome, TEN, or DRESS with prior modafinil/armodafinil use
Severe hepatic impairment (dose reduction required in moderate impairment)
Unstable angina or recent myocardial infarction
Left ventricular hypertrophy or clinically significant mitral valve prolapse with prior stimulant use
Pregnancy (limited human data; animal studies show teratogenicity at high doses)
Research Evidence
Melanotan II Modafinil
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2024 —
FDA Approved No Yes
More comparisons: BPC-157
This comparison is for educational and research purposes only. Consult a healthcare professional before use.